Compositions and methods for treating or preventing diseases of body passageways
The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.
1 . A method for treating or preventing an inflammatory disease associated with narrowing or obstruction of a body passageway, comprising delivering to an external portion of the body passageway of a patient in need thereof a therapeutically effective amount of an anti-angiogenic factor or a composition comprising an anti-angiogenic factor, such that the inflammatory disease is treated.
2 . The method of claim 1 wherein the disease is a gastrointestinal tract disease.
3 . The method of claim 2 wherein the gastrointestinal tract disease is selected from the group consisting of pancreatitis, Crohn's Disease, Ulcerative Colitis, Ulcerative Proctitis, and Primary Sclerosing Cholangitis.
4 . The method of claim 2 wherein the gastrointestinal tract disease is a benign stricture.
5 . The method of claim 4 wherein the benign stricture is selected from the group consisting of bile duct, esophagus, duodenum, small bowel and colon strictures.
6 . The method of claim 1 wherein the inflammatory disease is vasculitis.
7 . The method of claim 1 wherein the inflammatory disease is a respiratory tract disease.
8 . The method of claim 7 wherein the respiratory tract disease is asthma, hypersensitivity pneumonitis, asbestosis, silicosis, chronic bronchitis, or chronic obstructive airway disease.
9 . The method of claim 1 wherein the inflammatory disease is a nasolacrimal duct disease or eustachean tube disease.
10 . The method of claim 1 wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, sinus passages, eustachian tubes, and external auditory canal.
11 . The method of claim 1 wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, and a urethra.
12 . The method of claim 1 wherein the anti-angiogenic factor is a compound which disrupts microtubule function.
13 . The method of claim 12 wherein the compound is paclitaxel or a derivative or analogue thereof.
14 . The method of claim 13 wherein the compound is paclitaxel.
15 . The method of claim 13 wherein the compound is a derivative or analogue of paclitaxel.
16 . The method of claim 1 wherein the anti-angiogenic factor is mitoxantrone.
17 . The method of claim 1 wherein the anti-angiogenic factor is a metalloproteinase inhibitor.
18 . The method of claim 1 wherein the anti-angiogenic factor is angiostatin.
19 . The method of claim 1 wherein the anti-angiogenic factor is an anthracycline.
20 . The method of claim 1 wherein the composition is biodegradable.
21 . The method of claim 1 wherein the composition is non-biodegradable.
22 . The method of claim 1 wherein the composition further comprises a polymer.
23 . The method of claim 22 wherein the polymer is biodegradable.
24 . The method of claim 22 wherein the polymer is non-biodegradable.
25 . The method of claim 1 wherein the composition further comprises a copolymer of lactic acid and glycolic acid.
26 . The method of claim 1 wherein the composition further comprises a poly(caprolactone).
27 . The method of claim 1 wherein the composition further comprises a poly(lactic acid).
28 . The method of claim 1 wherein the composition further comprises a. copolymer of poly(lactic acid) and poly(caprolactone).
29 . The method of claim 1 wherein the composition further comprises a poly(ethylene-vinyl acetate).
30 . The method of claim 1 wherein the composition further comprises a polyester.
31 . The method of claim 1 wherein the composition further comprises a polyurethane.
32 . The method of claim 1 wherein the composition further comprises a polyanhydride.
33 . The method of claim 1 wherein the composition further comprises a gelatin.
34 . The method of claim 1 wherein the composition is in the form of a paste.
35 . The method of claim 1 wherein the composition is in the form of a film.
36 . The method of claim 1 wherein the composition is in the form of a spray.
37 . The method of claim 1 wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.
38 . The method of claim 1 wherein the anti-angiogenic factor or composition comprising the anti-angiogenic factor is administered percutaneously to the exterior surface of the body passageway.
39 . The method of claim 1 wherein the anti-angiogenic factor or composition comprising the anti-angiogenic factor is applied to the adventitial surface of the body passageway.
40 . A method for treating or preventing an inflammatory disease associated with narrowing or obstruction of a body passageway, comprising delivering to smooth muscle cells via the adventitia of the body passageway of a patient in need thereof a therapeutically effective amount of an anti-angiogenic factor or a composition comprising an anti-angiogenic factor, such that the inflammatory disease is treated.
41 . The method of claim 40 wherein the disease is a gastrointestinal tract disease.
42 . The method of claim 41 wherein the gastrointestinal tract disease is selected from the group consisting of pancreatitis, Crohn's Disease, Ulcerative Colitis, Ulcerative Proctitis, and Primary Sclerosing Cholangitis.
43 . The method of claim 41 wherein the gastrointestinal tract disease is a benign stricture.
44 . The method of claim 43 wherein the benign stricture is selected from the group consisting of bile duct, esophagus, duodenum, small bowel and colon strictures.
45 . The method of claim 40 wherein the inflammatory disease is vasculitis.
46 . The method of claim 40 wherein the inflammatory disease is a respiratory tract disease.
47 . The method of claim 46 wherein the respiratory tract disease is asthma, hypersensitivity pneumonitis, asbestosis, silicosis, chronic bronchitis, or chronic obstructive airway disease.
48 . The method of claim 40 wherein the inflammatory disease is a nasolacrimal duct disease or eustachean tube disease.
49 . The method of claim 40 wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, sinus passages, eustachian tubes, and external auditory canal.
50 . The method of claim 40 wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, and a urethra.
51 . The method of claim 40 wherein the anti-angiogenic factor is a compound which disrupts microtubule function.
52 . The method of claim 51 wherein the compound is paclitaxel or a derivative or analogue thereof.
53 . The method of claim 52 wherein the compound is paclitaxel.
54 . The method of claim 52 wherein the compound is a derivative or analogue of paclitaxel.
55 . The method of claim 40 wherein the anti-angiogenic factor is mitoxantrone.
56 . The method of claim 40 wherein the anti-angiogenic factor is a metalloproteinase inhibitor.
57 . The method of claim 40 wherein the anti-angiogenic factor is angiostatin.
58 . The method of claim 40 wherein the anti-angiogenic factor is an anthracycline.
59 . The method of claim 40 wherein the composition is biodegradable.
60 . The method of claim 40 wherein the composition is non-biodegradable.
61 . The method of claim 40 wherein the composition further comprises a polymer.
62 . The method of claim 61 wherein the polymer is biodegradable.
63 . The method of claim 61 wherein the polymer is non-biodegradable.
64 . The method of claim 40 wherein the composition further comprises a copolymer of lactic acid and glycolic acid.
65 . The method of claim 40 wherein the composition further comprises a poly(caprolactone).
66 . The method of claim 40 wherein the composition further comprises a poly(lactic acid).
67 . The method of claim 40 wherein the composition further comprises a copolymer of poly(lactic acid) and poly(caprolactone).
68 . The method of claim 40 wherein the composition further comprises a poly(ethylene-vinyl acetate).
69 . The method of claim 40 wherein the composition further comprises a polyester.
70 . The method of claim 40 wherein the composition further comprises a polyurethane.
71 . The method of claim 40 wherein the composition further comprises a polyanhydride.
72 . The method of claim 40 wherein the composition further comprises a gelatin.
73 . The method of claim 40 wherein the composition is in the form of a paste.
74 . The method of claim 40 wherein the composition is in the form of a film.
75 . The method of claim 40 wherein the composition is in the form of a spray.
76 . The method of claim 40 wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.